Skip to main content
SpringerLink
Log in

Spotlight on Paricalcitol in Secondary Hyperparathyroidism

  • Adis Spotlight
  • Published:
Treatments in Endocrinology

Abstract

Paricalcitol (Zemplar®) is a synthetic vitamin D2 analog that inhibits the secretion of parathyroid hormone (PTH) through binding to the vitamin D receptor. It is approved in the US and in most European nations for intravenous use in the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure in adult, and in the US pediatric, patients.

Paricalcitol effectively reduced elevated serum PTH levels and was generally well tolerated in children and adults with secondary hyperparathyroidism associated with chronic renal failure. In well designed clinical trials, paricalcitol was as effective as calcitriol and as well tolerated in terms of the incidence of prolonged hypercalcemia and/or elevated calcium-phosphorus product (Ca × P). Thus, paricalcitol is a useful option for the management of secondary hyperparathyroidism in adults and children with chronic renal failure.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Dusso AS, Thadhani R, Slatopolsky E. Vitamin D receptor and analogs. Semin Nephrol 2004; 24(1): 10–6

    Article  PubMed  CAS  Google Scholar 

  2. Slatopolsky E, Cozzolino M, Lu Y, et al. Efficacy of 19-nor-1,25-(OH)2D2 in the prevention and treatment of hyperparathyroid bone disease in experimental uremia. Kidney Int 2003 Jun; 63(6): 2020–7

    Article  PubMed  CAS  Google Scholar 

  3. Takahashi F, Finch JL, Denda M, et al. A new analog of 1,25-(OH)2D3, 19-nor-1,25-(OH)2D2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content. Am J Kidney Dis 1997 Jul; 30(1): 105–12

    Article  PubMed  CAS  Google Scholar 

  4. Cozzolino M, Lu Y, Finch J, et al. p21WAFl and TGF-α mediate parathyroid growth arrest by vitamin D and high calcium. Kidney Int 2001 Dec; 60(6): 2109–17

    Article  PubMed  CAS  Google Scholar 

  5. Balint E, Marshall CF, Sprague SM. Effect of the vitamin D analogues paricalcitol and calcitriol on bone mineral in vitro. Am J Kidney Dis 2000 Oct; 36(4): 789–96

    Article  PubMed  CAS  Google Scholar 

  6. Finch JL, Dusso AS, Pavlopoulos T, et al. Relative potencies of 1,25-(OH)2D3 and 19-nor-1,25-(OH)2D2 on inducing differentiation and markers of bone formation in MG-63 cells. J Am Soc Nephrol 2001 Jul; 12(7): 1468–74

    PubMed  CAS  Google Scholar 

  7. Slatopolsky E, Cozzolino M, Finch JL. Differential effects of 19-nor-1,25-(OH)2D2 and lα-hydroxyvitamin D2 on calcium and phosphorus in normal and uremic rats. Kidney Int 2002 Oct; 62(4): 1277–84

    Article  PubMed  CAS  Google Scholar 

  8. Brown AJ, Finch J, Slatopolsky E. Differential effects of 19-nor-l,25-dihydroxy-vitamin D2 and 1,25-dihydroxyvitamin D3 on intestinal calcium and phosphate transport. J Lab Clin Med 2002 May; 139(5): 279–84

    Article  PubMed  CAS  Google Scholar 

  9. Slatopolsky E, Finch J, Ritter C, et al. A new analog of calcitriol, 19-nor-l,25-(OH)2D2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia. Am J Kidney Dis 1995 Nov; 26(5): 852–60

    Article  PubMed  CAS  Google Scholar 

  10. Slatopolsky E, Cavanaugh J, Cato A. Pharmacokinetics of paracalcin (19-nor-l-α,25-dihydroxyvitamin D2) in healthy subjects [abstract no. p428]. Nephrology (Carlton) 1997 May; 3Suppl. 1: S182

    Google Scholar 

  11. Cato A, Buschen C, Ahmed A, et al. The pharmacokinetics of paracalcin [abstract no. PIII-95]. 98th annual meeting of the American Society for Clinical Pharmacology and Therapeutics; 1997 Mar 5–8; San Diego, 218

  12. Lee RD, Grabowski B, Johnson MK, et al. Disposition and excretion of [3H]19-nor-1α,25-dihyroxyvitamin D2 in humans [abstract no. S402]. J Bone Miner Res 1997; 12 Suppl.: S453

    Article  Google Scholar 

  13. Lutwak L. Medical officer’s review: paricalcitol injection [online]. Available from URL: http://www.fda.gov/cder/foi/nda/98/20819_Zemplar.htm [Accessed 2004 Sep 20]

  14. Schroeder NJ, Burrin JM, Noonan K, et al. Effects of ‘non-calcaemic’ vitamin D analogues on 24-hydroxylase expression in MG-63 osteoblast-like cells. Nephron Physiol 2003; 94(4): 62–73

    Article  Google Scholar 

  15. Cato A, Cady WW, Soltanek C, et al. Effect of hemodialysis on the pharmacokinetics of 19-nor-1-α,25-dihydroxyvitamin D2. Am J Kidney Dis 1998 Oct; 32(2 Suppl. 2): 55–60

    Google Scholar 

  16. Llach F, Keshav G, Goldblat MV, et al. Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue: 19-nor-1,25-dihydroxyvitamin D2. Am J Kidney Dis 1998 Oct; 32(4 Suppl. 2): S48–54

    Article  PubMed  CAS  Google Scholar 

  17. Martin KJ, Gonzalez EA, Gellens M, et al. 19-nor-1-α-25-dihydroxyvitamin D2 (paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 1998 Aug; 9(8): 1427–32

    PubMed  CAS  Google Scholar 

  18. Sprague SM, Llach F, Amdahl M, et al. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 2003 Apr; 63(4): 1483–90

    Article  PubMed  CAS  Google Scholar 

  19. Llach F, Yudd M. Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism. Am J Kidney Dis 2001 Nov; 38(5 Suppl. 5): S45–50

    Article  PubMed  CAS  Google Scholar 

  20. Melnick JZ, Kommala D, Mattingly S, et al. Paricalcitol and calcitriol in treating SHPT in children: a comparison of 2 studies [abstract no. SU-P0930]. Proceedings of the American Society of Nephrology; 2004 Oct 27–Nov 1; St Louis

  21. Teng M, Wolf M, Lowrie E, et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003 Jul 31; 349: 446–56

    Article  PubMed  CAS  Google Scholar 

  22. Zemplar. Clinical review: executive summary. Summaries of medical and clinical pharmacology reviews of pediatric studies [online]. Available from URL: http:/ /www.fda.gov/cder/foi/esum/2004/20819se5-014_zemplar_clinical_bpca.pdf [Accessed 2004 Sep 15]

  23. Abbott Laboratories. Zemplar® paricalcitol injection [online]. Available from URL: http://www.fda.gov [Accessed 2004 Sep 29]

Download references

Author information

Authors and Affiliations

  1. Adis International Inc., Yardley, 770 Township Line Road, Suite 300, Yardley, Pennsylvania, 19067, USA

    Dean M. Robinson & Lesley J. Scott

Authors
  1. Dean M. Robinson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lesley J. Scott
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dean M. Robinson.

Additional information

This Spotlight is derived from abstract and summary text of an Adis Drug Evaluation originally published in full in Drugs 2005 Feb; 65 (4): 559-576

Rights and permissions

Reprints and permissions

About this article

Cite this article

Robinson, D.M., Scott, L.J. Spotlight on Paricalcitol in Secondary Hyperparathyroidism. Mol Diag Ther 4, 185–186 (2005). https://doi.org/10.2165/00024677-200504030-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00024677-200504030-00007

Keywords

Search

Navigation